Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

Diabetologia

Volumn 48, Issue 6, 2005, Pages 1093-1104

  Charbonnel, B ^a   Schernthaner, G ^b   Brunetti, P ^c   Matthews, D R ^d   Urquhart, R ^e   Tan, M H ^f   Hanefeld, M ^g  

^a HÔTEL DIEU   (France)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^c UNIVERSITY OF PERUGIA   (Italy)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e Takeda Europe R and D Centre   (United Kingdom)

^f ELI LILLY AND COMPANY   (United States)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Add on; Gliclazide; Long term; Metformin; Pioglitazone; Sulphonylurea; Sustained; Type 2 diabetes

Indexed keywords

GLICLAZIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACUTE HEART FAILURE; ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION DISORDER; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEMALE; FLATULENCE; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LONG TERM CARE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLICLAZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; METFORMIN; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SAFETY; THIAZOLIDINEDIONES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 21344451651     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1751-1     Document Type: Article

References (36)

1. Groop LC (1992) Sulfonylureas in NIDDM. Diabetes Care 15:737-754
2. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC, UK Prospective Diabetes Study (UKPDS) Group (1998) UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 15:297-303
3. Turner RC (1998) The U.K. prospective diabetes study: a review. Diabetes Care 21(Suppl 3):C35-C38
4. UK Prospective Diabetes Study Group (1995) UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258
5. Turner RC, Cull CA, Frighi V, Holman RR, the UK Prospective Diabetes Study (UKPDS) Group (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005-2012
6. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL, the Pioglitazone 001 Study Group (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 23:1605-1611
7. Herz M, Johns D, Reviriego J et al and the GLAB Study Group (2003) A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naïve patients with type 2 diabetes mellitus. Clin Ther 25:1074-1095
8. Pavo I, Jermendy G, Varkonyi TT et al (2003) Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 88:1637-1645
9. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group (2001) The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 12:413-423
10. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P on behalf of the QUARTET Study Group (2005) A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 22:399-405
11. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, the Quartet Study Group (2004) Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068-6076
12. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL (2001) Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 111:10-17
13. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL, the Pioglitazone 027 Study Group (2000) Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 22:1395-1409
14. Derosa G, Cicero AFG, Gaddi A et al (2004) Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 26:744-754
15. Rendell MS, Glazer NB, Ye Z (2003) Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabetes Complications 17:211-217
16. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, on behalf of the QUARTET Study Group (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with Type 2 diabetes. Diabetes Care 27:141-147
17. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G (2005) Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes/Metab Res Rev 21:167-174
18. HDL). Clin Biochem 34:583-588
19. Johnson M, Krosnick A, Carson P, McDade AM, Laraway K (1998) A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes. Clin Ther 20:691-698
20. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549
21. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S (2001) Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 18:828-834
22. Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117
23. Stratton IM, Adler AI, Neil AW et al, on behalf of the UK Prospective Diabetes Study Group (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412
24. Dunn CJ, Peters DH (1995) Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49:721-749
25. UK Prospective Diabetes Study Group (1998) UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 21:87-92
26. Taskinsen M-R (2003) LDL-cholesterol, HDL-cholesterol or triglycerides - which is the culprit? Diabetes Res Clin Pract 61:
27. Fontbonne A, Eschwège E, Cambien F et al (1989) Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32:300-304
28. West KM, Ahuja MMS, Bennett PH et al (1983) The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 6:361-369
29. Wilson PWF, Kannel WB, Anderson KM (1985) Lipids, glucose intolerance and vascular disease: the Framingham Study. Monogr Atheroscler 13:1-11
30. Lehto S, Rönnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M (1997) Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354-1359
31. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM (1988) Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921
32. Campos H, Genest JJ Jr, Blijlevens E et al (1992) Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 12:187-195
33. Coresh J, Kwiterovich PO Jr, Smith HH, Bachorik PS (1993) Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 34:1687-1697
34. Gardner CD, Fortmann SP, Krauss RM (1996) Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276:875-881
35. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM (1992) LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 12:1496-1502
36. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A (2004) The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care 27:1647-1653